Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1999-06-22
2000-11-07
Huff, Sheela
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303877, 53038722, 53038873, 5303887, 5303888, 5303896, 5303897, 4241361, 4241383, 4241441, 4241531, 4241551, 4241731, 4241741, 435326, 435328, 435330, 435334, 4353431, 435344, 435449, 435 711, A61K 39395, C12N 1506
Patent
active
061438731
ABSTRACT:
This invention relates generally to the field of immunology, in particular that of antibodies and antibody productions. More specifically, this invention relates to bispecific antibodies, the hybrid hybridomas which produce them, the parent hybridomas, the production and selection of the hybridomas and hybrid hybridomas, and the purification of the bispecific antibodies. Specific examples relate to bispecific monoclonal antibodies which recognize both the human multi-drug resistance antigen, P-glycoprotein and human Fc.gamma. receptor III (hFc.gamma.RIII. These bispecific antibodies are useful in killing cancer cells.
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4676980 (1987-06-01), Segal et al.
Shi et al., Clinical Immunology and Immunopathology 76:44-51, 1995.
Aihara et al., Blood 77:2079-2084, 1991.
Bohurs et al., Int. J. Cancer 7:78-81 (1992).
Bolhuis et al., "Adoptive Immunotherapy of Ovarian Carcinoma with BS-MAb-Targeted Lymphocytes: A Multicenter Study," Int. J. Cancer: Supplement 7:78-81 (1992).
Bonardi et al., "Initial Experience in Treating Human Lymphoma with a Combination of Bispecific Antibody and Saporin," Int. J. Cancer: Supplement 7:73-71 (1992).
DeLau et al., "Absence of Preferential Homologous H/L Chain Association in Hybrid Hybridomas," The Journal of Immunology 146(3):906-914 (1991).
Demanet et al., "Bispecific Antibody Therapy of Two Murine B-Cell Lymphomas," Int. J. Cancer Supplement 7:67-68 (1992).
de Palazzo et al., "Antitumor Effects of a Bispecific Antibody Targeting CA19-9 Antigen and CD16," Cancer Research 52:5713-5719 (1992).
Fanger et al., "Bispecific Antibodies and Targeted Cellular Cytotoxicity," Immunology Today 12(2):51-54 (1991).
Greenman et al., "Comparative Efficiencies of Bispecific F(ab'.gamma.) and Chimeric Mouse/Human IgG Antibodies in Recruiting Cellular Effectors for Cytotoxicity Via Fc.gamma. Receptors," Cancer Immunol. Immunotherapy 34:361-369 (1992).
Hamada et al., PNAS 83:7785 (1986).
Harris et al., TibTech 11:42 (1993).
Hird et al., Genes and Cancer Wiley and Sing Ltd. p. 183 (1990).
Houghton et al., Seminars in Oncology 13(2):165-179 (1986).
Karpovsky et al., J. Exp. Med. 160:1686 (1984).
Nitta et al., "Preliminary Trial of Specific Targeting Therapy Against Malignant Glioma," The Lancet 35:368-371 (1990).
Perez et al., Nature 316:354 (1985).
Ring et al., "Targeted Lysis of Human Breast Cancer Cells by Human Effector Cells Armed With Bispecific Antibody 2B1 (Anti-c-erbB-2/Anti-Fc.gamma. Receptor III)," Breast Epithelial Antigens Abstract pp. 91-104 (1991).
Staerz et al., Proc. Natl Acad. Science 83:1453-1457 (1986).
Staerz et al., Immunology Today 7:241 (1986).
Staerz et al., Nature 314:628 (1985).
Titus et al., J. Immunol. 138:4018 (1987).
Titus et al., Journal of Immunology 139(9):3153-3158 (1987).
Unkeless, J. Exp. Med 150(9):580-596 (1979).
Van Dijk et al., Int. J. Cancer 44:738-743 (1989).
Waldmann, Science 252:1657 (1991).
Weiner et al., "A Human Tumor Xenograft Model of Therapy with a Bispecific Monoclonal Antibody Targeting c-erbB-2 and CD16," Cancer Research 53:94-100 (1993).
Weiner, George J., "Bispecific IgG and IL-2 Therapy of a Syngeneic B-Cell Lymphoma in Immunocompetent Mice," Int. J. Cancer: Supplement 7:63-66 (1992).
Ring David
Shi Tian-Xiang
Blackburn Robert P.
Chiron Corporation
Fabian Gary R.
Helms Larry R.
Huff Sheela
LandOfFree
Monoclonal anti-multiple drug resistance antibody, methods of pr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal anti-multiple drug resistance antibody, methods of pr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal anti-multiple drug resistance antibody, methods of pr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1642463